These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35213729)

  • 1. Response to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS".
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 May; 107(6):e2651-e2652. PubMed ID: 35213729
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS".
    Taguchi A
    J Clin Endocrinol Metab; 2022 May; 107(6):e2646. PubMed ID: 35213697
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteonecrosis of the jaw].
    Drozdzowska B
    Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the Jaw.
    Hamdy RC
    J Clin Densitom; 2017; 20(1):1-2. PubMed ID: 28259260
    [No Abstract]   [Full Text] [Related]  

  • 8. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.
    Thiel Y; Ghayor C; Lindhorst D; Essig H; Weber F; Rücker M; Schumann P
    Pathol Res Pract; 2020 Dec; 216(12):153245. PubMed ID: 33065485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
    Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
    Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.
    Rossi M; Gambino A; Cabras M; Alessio M; Fusco V
    Support Care Cancer; 2021 Aug; 29(8):4185-4186. PubMed ID: 33634351
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
    Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
    Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
    Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
    Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw.
    Allegra A; Innao V; Pulvirenti N; Musolino C
    Tohoku J Exp Med; 2019 May; 248(1):27-29. PubMed ID: 31080196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A current update on osteonecrosis of the jaw and bisphosphonates.
    Arrain Y; Masud T
    Dent Update; 2011 Dec; 38(10):672-6, 678. PubMed ID: 22408887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction.
    Tagliamento M; Boutros C; Viansone A; Brau JJ; Descols P
    Eur J Cancer; 2022 May; 166():33-37. PubMed ID: 35272085
    [No Abstract]   [Full Text] [Related]  

  • 20. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
    Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
    Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.